Evidence map›Paper›PMID 30697747›Full record

ArticleJournal of neurochemistry2019

Venlafaxine stimulates PNN proteolysis and MMP-9-dependent enhancement of gamma power; relevance to antidepressant efficacy.

Seham Alaiyed, P Lorenzo Bozzelli, Adam Caccavano, Jian Young Wu, Katherine Conant

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 52 citations in OpenAlex.

  1. Parvalbumin interneurons under stress: converging mechanisms of vulnerability.The international journal of neuropsychopharmacology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Seham AlaiyedDepartments of Pharmacology, Georgetown University Medical Center, Washington, District of Columbia, USA.ORCID 0000-0003-3289-4291
P Lorenzo BozzelliDepartments of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.ORCID 0000-0002-3760-521X
Adam CaccavanoDepartments of Pharmacology, Georgetown University Medical Center, Washington, District of Columbia, USA.ORCID 0000-0002-6819-533X
Jian Young WuDepartments of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.
Katherine ConantDepartments of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.ORCID 0000-0003-3882-9810
Georgetown University · US

Funding

Predoctoral Training in Intergrative NeuroscienceT32NS041231 · NINDS · GEORGETOWN UNIVERSITY · PI Ludise Malkova, Ashley S VanMeter · 2001 to 2026
$6.8M
Translational Biomedical Science Training GrantTL1TR001431 · NCATS · GEORGETOWN UNIVERSITY · PI LEE, DEXTER L, SANDBERG, KATHRYN L · 2015 to 2024
$4.8M
Training in Neural Injury &PlasticityT32NS041218 · NINDS · GEORGETOWN UNIVERSITY · PI MARK P BURNS, Kathleen Anne Maguire-Zeiss · 2001 to 2026
$3.5M
Perineuronal proteolysis and circuit dysfunction in HANDR01NS108810 · NINDS · GEORGETOWN UNIVERSITY · PI CONANT, KATHERINE E, MAGUIRE-ZEISS, KATHLEEN ANNE · 2018 to 2022
$1.9M
NCATS NIH HHS TL1 TR001431NINDS NIH HHS R01 NS108810NINDS NIH HHS T32 NS041218NINDS NIH HHS T32 NS041231
6 · The paper itself

Abstract

Drugs that target monoaminergic transmission represent a first-line treatment for major depression. Though a full understanding of the mechanisms that underlie antidepressant efficacy is lacking, evidence supports a role for enhanced excitatory transmission. This can occur through two non-mutually exclusive mechanisms. The first involves increased function of excitatory neurons through relatively direct mechanisms such as enhanced dendritic arborization. Another mechanism involves reduced inhibitory function, which occurs with the rapid antidepressant ketamine. Consistent with this, GABAergic interneuron-mediated cortical inhibition is linked to reduced gamma oscillatory power, a rhythm also diminished in depression. Remission of depressive symptoms correlates with restoration of gamma power. As a result of strong excitatory input, reliable GABA release, and fast firing, PV-expressing neurons (PV neurons) represent critical pacemakers for synchronous oscillations. PV neurons also represent the predominant GABAergic population enveloped by perineuronal nets (PNNs), lattice-like structures that localize glutamatergic input. Disruption of PNNs reduces PV excitability and enhances gamma activity. Studies suggest that monoamine reuptake inhibitors reduce integrity of the PNN. Mechanisms by which these inhibitors reduce PNN integrity, however, remain largely unexplored. A better understanding of these issues might encourage development of therapeutics that best up-regulate PNN-modulating proteases. We observe that the serotonin/norepinephrine reuptake inhibitor venlafaxine increases hippocampal matrix metalloproteinase (MMP)-9 levels as determined by ELISA and concomitantly reduces PNN integrity in murine hippocampus as determined by analysis of sections following their staining with a fluorescent PNN-binding lectin. Moreover, venlafaxine-treated mice (30 mg/kg/day) show an increase in carbachol-induced gamma power in ex vivo hippocampal slices as determined by local field potential recording and Matlab analyses. Studies with mice deficient in matrix metalloproteinase 9 (MMP-9), a protease linked to PNN disruption in other settings, suggest that MMP-9 contributes to venlafaxine-enhanced gamma power. In conclusion, our results support the possibility that MMP-9 activity contributes to antidepressant efficacy through effects on the PNN that may in turn enhance neuronal population dynamics involved in mood and/or memory. Cover Image for this issue: doi: 10.1111/jnc.14498.

Indexed as

AnimalsAntidepressive Agents, Second-GenerationFemaleGamma RhythmHippocampusMaleMatrix Metalloproteinase 9MiceMice, Inbred C57BLNerve NetNeuronsProteolysisVenlafaxine HydrochlorideAntidepressive Agents, Second-GenerationMatrix Metalloproteinase 9Mmp9 protein, mouseVenlafaxine Hydrochloridedepressiongamma oscillationsinterneuronMMP-9perineuronal netvenlafaxine

Identifiers

PMID30697747
PMCPMC6516074
OpenAlexW2949368773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.